VICTOR RIGDON CAN fix just about anything. A carpenter at the Indiana State Fairgrounds, he repairs buildings, restores benches and flower boxes—anything. But three years ago, Rigdon found something he couldn’t fix. His cough. Rigdon didn’t hack. He didn’t ache. It was just a light cough. When he left a walk-in medical clinic with a prescription for antibiotics, Rigdon figured the cough would soon be gone. Ten days later, Rigdon sat in an exam room and stared as his physician […]
VICTOR RIGDON CAN fix just about anything. A carpenter at the Indiana State Fairgrounds, he repairs buildings, restores benches and flower boxes—anything. But three years ago, Rigdon found something he couldn’t fix.
didn’t hack. He didn’t ache. It was just a light cough. When he left a walk-in
medical clinic with a prescription for antibiotics, Rigdon figured the cough
would soon be gone.
days later, Rigdon sat in an exam room and stared as his physician showed him a
scan of his lungs—the left brimming with fluid. It led to a referral to a
pulmonologist, a biopsy—all ominous signs.
had non-small cell lung cancer—stage 4. It had gained a foothold in Rigdon’s
lung and spine. The most optimistic outlook gave him a year to live. “There had
been no warning,” Rigdon said. “Now, it was like, it’s spread. It’s terminal.”
What followed, though, was a
workmanlike process that led Durm to pull from his bag one of the newest tools
in cancer treatment—one being developed right here at IU.
WHEN LUNG CANCER takes root in a patient’s bone, it’s deemed incurable. The objective of treatment shifts from a cure to wrestling the disease into submission. For Rigdon, 49, it means facing a siege that will span decades.
knew two decades of smoking could exact a toll, but he figured it was still
years away. “I just didn’t think at that age it was going to happen,” he
the aftermath of the diagnosis, Rigdon embarked on a well-worn path for lung
cancer patients—four rounds of chemotherapy. Scans revealed a stalemate: His
cancer wasn’t spreading, but the tumors weren’t shrinking.
Durm, treating patients has some similarities to Rigdon’s craft. Each case
requires his expertise and an assortment of tools to solve a vexing problem.
Every patient comes with their own disease, set of genetic factors and
it was just a recipe for each patient, you wouldn’t really need doctors,” Durm
said. “You would just plug their information into a computer.”
is a physician who also works doggedly to find innovative treatments. Alongside
fellow researchers at IU Simon Cancer Center, he’s exploring how immunotherapy drugs—which boost
the body’s own defenses to fight cancer—can be used alone, or in tandem,
with traditional chemotherapy.
of the pressing questions facing oncologists today is what to do once an
immunotherapy drug stops working. Move on to another chemotherapy drug? Combine
immunotherapy with chemo?
another way, how could Durm help patients in the same predicament as Rigdon?
considered switching up chemotherapy drugs but knew the odds of success were
slim. Instead, he pitched another option: a recently approved immunotherapy
drug called Tencentriq. The drug blocks a protein on the surface of cancer cells—a checkpoint
inhibitor–unmasking them and enabling immune cells to snuff them out.
was also an ideal candidate—relatively young and unscathed by chemotherapy. After
his diagnosis, he remained well enough to take extended trips to the Gulf
Coast, Seattle, and to Maryland. He also returned to work at the Indiana State
Durm floated the idea of the new drug, Rigdon quickly concluded: “I can’t not do
His immune system was in a good state that it could sort of be enhanced by this drug. He didn’t get any side effects, which is actually not uncommon. We have tons of patients on immunotherapies who don’t get any side effects from these medicines.
Greg Durm, MD, on Victor Rigdon’s response to immunotherapy
THE RESULTS WERE nearly instant. After a few treatments, the cancer significantly shrunk in size.
immune system was in a good state that it could sort of be enhanced by this
drug. He didn’t get any side effects, which is actually not uncommon,” Durm
said. “We have tons of patients on immunotherapies who don’t get any side
effects from these medicines.”
like Tencentriq are steadily becoming frontline therapies, and Durm is leading
a clinical trial investigating how well they work when paired with chemotherapy
drugs. The approach is unique, and the entire project—design, patient
recruitment and data analysis—will take place at IU.
As the state’s lone academic health center, IU draws a diverse group of patients to Indianapolis and IU Simon Cancer Center, which is a hub for such trials and research. Researchers like Durm also tap into the expertise of the Hoosier Cancer Research Network to find additional sites, get clarity of regulatory questions, and receive advice on protocols.
has benefited from charitable gifts from donors like the Indiana Elks. The
support covers the nuts and bolts of conducting novel research–data entry, a
research nurse to ensure patients qualify for a trial, and additional lab
testing. Bland as those might sound, they’re pivotal in answering the kinds of
questions that save patients’ lives.
it, a lot of junior faculty would fail,” Durm said. “They fund a lot of the
correlative research we do, and that really helps us understand why something
worked or didn’t.”
Rigdon’s disease remains in check. His treatment amounts to getting stuck with a needle every three weeks and taking a half-day off from work. “If ain’t broke, don’t fix, right?” Rigdon says. And he has other, more pressing concerns–like the itinerary for his next trip.
“It’s been part of my decision to just do things,” he said. “I’m just going to live as long as I can and as well as I can. This probably keeps me feeling well and has me kept me healthy.”
To learn more about or support lung cancer research at IU School of Medicine, contact Amber Kleopfer Senseny at firstname.lastname@example.org or 317-278-4510.